What's New

Nippon Kayaku launches Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK”, a humanized anti-human HER2 monoclonal Antibody

2018/08/20

Tokyo, Japan, August 20, 2018 - Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Masanobu Suzuki; hereinafter referred to as “Nippon Kayaku”) today announced that it has launched the sale of Trastuzumab BS for I.V. Infusion 60mg “NK” ・150mg “NK”(hereinafter referred to as “Trastuzumab BS “NK”).

Trastuzumab BS “NK” is a biosimilar of the trastuzumab humanized anti-human HER2 monoclonal antibody. In this March, Nippon Kayaku obtained the manufacture and marketing approval with the indication of advanced or recurrent gastric cancer overexpressing HER2. Celltrion group has already received approvals in EU and Korea. Nippon Kayaku began development of Trastuzumab BS “NK” in November 2010 according to a cooperation agreement with the Celltrion group.

Trastuzumab BS “NK” is the second monoclonal antibody biosimilar for Nippon Kayaku following Infliximab BS for I.V. Infusion 100mg “NK”. With the marketing of Trastuzumab BS “NK”, we expect to make a significant contribution to the patients, their families and medical professionals.

[Reference material—Profile of Celltrion Inc.]
Company nameCelltrion Inc.
LocationIncheon, South Korea
ListingKOSPI
Business areasHeadquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EMA approval for InflectraTM and RemsimaTM, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. Celltrion also received EMA approval for TruximaTM (CT-P10, a mAb biosimilar to rituximab) in February 2017, and HerzumaTM (CT-P6, a mAb biosimilar to trastuzumab) received EMA approval in February 2018.

Celltrion Healthcare Co., Ltd. is the company which possesses exclusive global distribution and marketing rights to all Celltrion Inc. products.
Link http://www.celltrion.com/


[Please direct inquiries regarding this matter to:]
Telephone: +81- 3- 6731- 5237
Public Relations & Investor Relations Division
Nippon Kayaku Co., Ltd.
PageTop
Corporate Vision
Our Business
Corporate Information
Global Netowork
Investor Relations
CSR